Apimeds Pharmaceuticals US annual free cash flow
2025
Apimeds Pharmaceuticals US Free Cash Flow (FCF) History (APUS)
Apimeds Pharmaceuticals US reported −$9.0M in free cash flow for fiscal 2025.
View full Apimeds Pharmaceuticals US company overviewApimeds Pharmaceuticals US free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.0M | — | — | — |
Apimeds Pharmaceuticals US quarterly free cash flow
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$5.7M | — | — | — |
| Q1 2026 | 2026-03-31 | −$2.1M | — | — | — |
| Q4 2025 | 2025-12-31 | −$3.8M | — | — | — |
| Q3 2025 | 2025-09-30 | −$1.7M | — | — | — |
Apimeds Pharmaceuticals US free cash flow growth trends
Apimeds Pharmaceuticals US's latest reported quarter, Q2 2026, generated −$5.7M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Apimeds Pharmaceuticals US source filings ↗